CapsoVision (NASDAQ:CV) Earns Speculative Buy Rating from Analysts at Benchmark

Benchmark assumed coverage on shares of CapsoVision (NASDAQ:CV) in a report published on Monday, MarketBeat reports. The brokerage issued a speculative buy rating and a $5.00 price target on the stock.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of CapsoVision to a “hold” rating in a research note on Sunday, July 13th. Roth Capital set a $6.00 target price on shares of CapsoVision and gave the company a “buy” rating in a research note on Monday.

CapsoVision Trading Down 9.5%

Shares of NASDAQ:CV opened at $4.11 on Monday. CapsoVision has a 52-week low of $3.49 and a 52-week high of $5.72.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.